Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Vemurafenib/Cobimetinib in BRAF-mutant Melanoma
NCT01495988Phase 2Terminated
- Start
- Aug 2013
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in melanoma. Started Aug 2013; status: terminated.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01495988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495988.